Compare NBTB & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBTB | IMNM |
|---|---|---|
| Founded | 1856 | 2006 |
| Country | United States | United States |
| Employees | 2303 | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.5B |
| IPO Year | 1995 | 2020 |
| Metric | NBTB | IMNM |
|---|---|---|
| Price | $50.06 | $19.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 16 |
| Target Price | ★ $57.50 | $35.20 |
| AVG Volume (30 Days) | 316.9K | ★ 1.3M |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.17% | N/A |
| EPS Growth | 12.12 | ★ 51.40 |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $182,952,000.00 | $6,941,000.00 |
| Revenue This Year | $8.99 | N/A |
| Revenue Next Year | $5.53 | $18,747.97 |
| P/E Ratio | $25.39 | ★ N/A |
| Revenue Growth | ★ 10.40 | N/A |
| 52 Week Low | $39.21 | $13.53 |
| 52 Week High | $54.50 | $30.06 |
| Indicator | NBTB | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 41.88 | 30.12 |
| Support Level | $49.75 | $19.39 |
| Resistance Level | $51.09 | $23.48 |
| Average True Range (ATR) | 0.77 | 1.12 |
| MACD | -0.05 | -0.27 |
| Stochastic Oscillator | 29.02 | 13.81 |
NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.